Catalyst Pharmaceuticals Stock In The News
| CPRX Stock | USD 15.12 0.39 2.65% |
The overall news coverage of Catalyst Pharmaceuticals from major news outlets shows solid bullish sentiment on 8 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Catalyst Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Catalyst Pharmaceuticals. The specific impact of Catalyst Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Catalyst Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Catalyst Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Catalyst Pharmaceuticals Backtesting and Catalyst Pharmaceuticals Hype Analysis. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Catalyst |
Catalyst Pharmaceuticals Today Top News and Investor Outlook
Catalyst Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Catalyst and other traded companies coverage. We help investors stay connected with Catalyst headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on Catalyst Stock performance. Please note that trading solely based on the Catalyst Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.Catalyst Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Catalyst earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Largest EPS Surprises
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2018-11-07 | 2018-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2018-08-07 | 2018-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2017-08-09 | 2017-06-30 | -0.06 | -0.05 | 0.01 | 16 |
Catalyst Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Catalyst Pharmaceuticals Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.
22nd of April 2024
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 at finance.yahoo.com
15th of April 2024
Catalyst Pharmaceutical Misses Q1 Earnings Estimates - Yahoo Movies UK at news.google.com
8th of April 2024
Acquisition by David Tierney of 25000 shares of Catalyst Pharmaceuticals at 4.01 subject t... at MacroaxisInsider
28th of March 2024
Catalyst Pharmaceuticals executive sells over 400k in company stock at investing.com
27th of March 2024
The three-year decline in earnings might be taking its toll on Catalyst Pharmaceuticals sh... at simplywall.st
22nd of March 2024
Investors in Catalyst Pharmaceuticals have seen strong returns of 271 percent over the pas... at finance.yahoo.com
19th of March 2024
Acquisition by Donald Denkhaus of 40000 shares of Catalyst Pharmaceuticals at 4.01 subject... at news.google.com
14th of March 2024
Santheras Partner Catalyst Pharmaceuticals Launches AGAMREE in the United States at streetinsider.com
5th of March 2024
Catalyst Pharmaceuticals, Inc. Short Interest Update at thelincolnianonline.com
16th of February 2024
Exercise or conversion by David Tierney of 4000 shares of Catalyst Pharmaceuticals subject... at MacroaxisInsider
Catalyst Pharmaceuticals Investors Sentiment
The influence of Catalyst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Catalyst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Catalyst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalyst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalyst Pharmaceuticals' short interest history, or implied volatility extrapolated from Catalyst Pharmaceuticals options trading.
Check out Catalyst Pharmaceuticals Backtesting and Catalyst Pharmaceuticals Hype Analysis. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.